Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 2:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 232 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Enhanced Label Clear all
Completed No phase listed Observational Accepts healthy volunteers

Muscle OXPHOS and Nutrient Homeostasis

NCT02920671
View directory record Official record
Conditions
Mitochondrial Diseases, Obesity
Interventions
Tracer-enhanced oral glucose tolerance test (OGTT*), Muscle MRI, Dual energy x-ray absorptiometry (DXA), Questionnaires
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Oct 30, 2026, 2:00 AM EDT
Completed Not applicable Interventional Results available

PET/CT-Assessment of Liver Tumor Ablation

NCT02018107
View directory record Official record
Conditions
Liver Tumor, Liver Neoplasms
Interventions
N-13 ammonia or F-18 fluorodeoxyglucose, PET scan
Diagnostic Test
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced Oct 30, 2026, 2:00 AM EDT
Recruiting Phase 1 Interventional

Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252

NCT06126744
View directory record Official record
Conditions
Recurrent High Grade Glioma
Interventions
MVR-C5252
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
New York, New York • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 30, 2026, 2:00 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Release Kinetics of rhBMP-2 Using E-PRF as an Autologous Carrier: An In Vitro Analysis

NCT04670965
View directory record Official record
Conditions
Bone Loss
Interventions
E-PRF/rhBMP-2 (similar ratios), E-PRF/ACS/rhBMP-2, rhBMP-2/E-PRF, E-PRF only
Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 30, 2026, 2:00 AM EDT
Completed Phase 2 Interventional Results available

Contrast-Enhanced Ultrasound for Kidney Cancer Subtyping and Staging

NCT04021238
View directory record Official record
Conditions
Kidney Cancer
Interventions
Perflutren lipid microsphere, Sulfur hexafluoride lipid microspheres
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 30, 2026, 2:00 AM EDT
Completed Phase 2 Interventional Results available

Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney

NCT00035555
View directory record Official record
Conditions
Graft Rejection, Kidney Transplantation, Renal Transplantation
Interventions
Belatacept, Cyclosporine, Mycophenolate mofetil (MMF), Corticosteroids
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
12
States / cities
San Francisco, California • Atlanta, Georgia • Baltimore, Maryland + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Oct 30, 2026, 2:00 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Scaling CRC Screening Through Outreach, Referral, and Engagement (SCORE)

NCT04406714
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Trial Mailed FIT Intervention - Age Group 50-75, Sub-Study Mailed FIT Intervention Enhanced Envelope - Age Group 45-49, Sub-Study Mailed FIT Active Comparator Plain Envelope - Age Group 45-49
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
45 Years to 75 Years
Enrollment
4,318 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
2
States / cities
Ahoskie, North Carolina • Hendersonville, North Carolina
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 30, 2026, 2:00 AM EDT
Completed Not applicable Interventional

Enhanced Spanish Drug Label Study to Promote Patient Understanding and Use

NCT01200849
View directory record Official record
Conditions
Medication Understanding, Diabetes, Hypertension
Interventions
Enhanced Label
Other
Lead sponsor
Northwestern University
Other
Eligibility
30 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 18, 2014 · Synced Oct 30, 2026, 2:00 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Nicotine Treatment of Cognitive Decline in Down Syndrome

NCT01778946
View directory record Official record
Conditions
Down Syndrome, Mild Cognitive Impairment
Interventions
Low Dose Nicotine (7mg), Moderate Dose Nicotine (14mg)
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
25 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 30, 2026, 2:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral-COVID-19 in Normal Healthy Volunteers

NCT04591717
View directory record Official record
Conditions
COVID-19
Interventions
hAd5-S-Fusion+N-ETSD vaccine
Biological
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
2
States / cities
El Segundo, California • Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Oct 30, 2026, 2:00 AM EDT
Completed Phase 4 Interventional

Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Optimark (Gadoversetamide) in Pediatric Patients

NCT01092754
View directory record Official record
Conditions
Pathological Processes
Interventions
MRI, Gadoversetamide
Procedure · Drug
Lead sponsor
Guerbet
Industry
Eligibility
2 Years to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
12
States / cities
Little Rock, Arkansas • San Diego, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Oct 30, 2026, 2:00 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Integrin Alpha-v-Beta and [18F]-R01-MG-F2 PET/CT in Measuring Response in Patients With Pancreatic Cancer and Healthy Volunteers

NCT02683824
View directory record Official record
Conditions
Healthy Subject, Pancreatic Carcinoma
Interventions
Computed Tomography, Laboratory Biomarker Analysis, PET/MRI scan, [18F]FP-R01-MG-F2
Diagnostic Test · Other · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 30, 2026, 2:00 AM EDT
Completed Not applicable Interventional Results available

Efficacy of VR101 as a Personal Lubricant

NCT04288752
View directory record Official record
Conditions
Sexual Dysfunction, Physiological
Interventions
VR101 Lubricating Intravaginal Ring, Sham Ring
Device
Lead sponsor
J3 Bioscience, Inc.
Industry
Eligibility
21 Years and older · Female only
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
Meridian, Idaho • West Jordan, Utah
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Oct 30, 2026, 2:00 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)

NCT01104584
View directory record Official record
Conditions
Breast Cancer
Interventions
Gadobutrol (Gadavist, Gadovist, BAY86-4875)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
9
States / cities
Tucson, Arizona • Oakland, California • Englewood, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2014 · Synced Oct 30, 2026, 2:00 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-Volume PrEP Site in the United States

NCT05374525
View directory record Official record
Conditions
HIV Infections
Interventions
APRETUDE, Cabotegravir OLI
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older · Male only
Enrollment
287 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
17
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 30, 2026, 2:00 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Mail Outreach To Increase Vaccination Acceptance Through Engagement

NCT02243774
View directory record Official record
Conditions
Influenza, Human, Influenza, Human Flu
Interventions
Core letter signed by Surgeon General, Core letter signed by the Director of the National Vaccine Program, Core letter signed by Surgeon General + implementation prompt, Core letter signed by SG + enhanced implementation prompt
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
66 Years and older
Enrollment
228,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Oct 30, 2026, 2:00 AM EDT
Completed Phase 4 Interventional

Gadolinium Contrast-enhanced Abbreviated MRI (AMRI) vs. Standard Ultrasound for Hepatocellular Carcinoma (HCC) Surveillance in Patients With Cirrhosis

NCT04288323
View directory record Official record
Conditions
Liver Cancer, Liver Cirrhoses, Liver Carcinoma
Interventions
Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 30, 2026, 2:00 AM EDT
Active, not recruiting Phase 3 Interventional

Psilocybin for Major Depressive Disorder (MDD)

NCT06308653
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Psilocybin 25 mg, Inactive Placebo, Psilocybin 5 mg, Psychosocial Support
Drug · Behavioral
Lead sponsor
Usona Institute
Other
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
29
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 30, 2026, 2:00 AM EDT
Completed Phase 3 Interventional Results available

Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)

NCT01890421
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Gadobutrol (Gadovist, Gadavist, BAY86-4875)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 16, 2018 · Synced Oct 30, 2026, 2:00 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cigarette Pack Inserts for Smoking Cessation

NCT04075682
View directory record Official record
Conditions
Smoking Cessation
Interventions
Inserts with efficacy messages, Pictorial warnings on packs
Other
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
387 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
2
States / cities
Ithaca, New York • Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated May 13, 2024 · Synced Oct 30, 2026, 2:00 AM EDT
Completed Phase 1 Interventional

A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients

NCT02253264
View directory record Official record
Conditions
Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Interventions
Rituximab
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Oct 30, 2026, 2:00 AM EDT
Completed Not applicable Interventional Results available

Novel PET/CT and Treatment Strategies to Reduce PTS Following DVT

NCT03195777
View directory record Official record
Conditions
Deep Venous Thrombosis, Post-thrombotic Syndrome
Interventions
PET/CT
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
30 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 30, 2026, 2:00 AM EDT
Completed Phase 4 Interventional Results available

CAE Plus LAI in Individuals With Bipolar Disorder at Risk for Treatment Non-adherence (BD-CAEL)

NCT03408873
View directory record Official record
Conditions
Bipolar Disorder, Medication Adherence, Medication Non Adherence
Interventions
Abilify Maintena, Customized Adherence Enhancement (CAE)
Drug · Behavioral
Lead sponsor
Martha Sajatovic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 17, 2022 · Synced Oct 30, 2026, 2:00 AM EDT
Completed Not applicable Interventional

Enhancing Self-Management Support in Diabetes Through Patient Engagement

NCT02834923
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Enhanced Engagement Protocol for CTH (EE-CTH), Connection to Health (CTH)
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older
Enrollment
725 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2021 · Synced Oct 30, 2026, 2:00 AM EDT